Frederick G.L. Huetwell Professor of Rheumatology and Director, Scleroderma Program, University of Michigan
| Role | Organisation | Sources |
|---|---|---|
| Frederick G.L. Huetwell Professor of Rheumatology and Director, Scleroderma Program | University of Michigan | Brandon Capital, Brandon BioCatalyst |
Stories naming Professor Dinesh Khanna. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.